secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2026-08-11T11:05:26+00:00
Accession:  0001193125-26-343408
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura cuts 20% workforce, refocuses on ocular oncology; Q2 cash $323.8M
----------------------------------------------------------------------

- Q2 2026 cash and equivalents $323.8M; R&D expense $30.7M (up from $22.9M YoY).
- Phase 3 CoMpass fully enrolled (108 patients); topline data expected 2H 2027.
- Workforce reduction ~20% with $2.9-3.2M estimated costs; NMIBC program deprioritized.
- CFO Tony Gibney departs Sept 1, 2026; Amy Elazzouzi named interim principal financial officer.
- Susan Abu-Absi appointed COO; base salary $520K and equity award ~400K shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312526343408/0001193125-26-343408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312526343408/aura-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer